MIRA INFORM REPORT

 

 

Report Date :

05.12.2011

 

IDENTIFICATION DETAILS

 

Name :

MARPEL PHARMA S.A.

 

 

Registered Office :

Calle Mata Palo, Multibodegas No.7, frente al Colegio San José, Blue Valley, Guachipelín Escazú San José

 

 

Country :

Costa Rica

 

 

Year of Establishment :

July 2004

 

 

Legal Form :

Joint-Stock Company

 

 

Line of Business :

Import and trading of (finished) pharmaceutical products for human consumption, as well as inputs for manufacturing them.

 

 

No. of Employees :

50 (22 in Costa Rica, 28 in branches)

 

RATING & COMMENTS

 

MIRA’s Rating :

B

 

RATING

STATUS

PROPOSED CREDIT LINE

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

Small

 

Maximum Credit Limit :

US$30,000

Status :

Moderate

Payment Behaviour :

No Complaints

Litigation :

Clear

 

NOTES :

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – September 30, 2011

 

Country Name

Previous Rating

(30.06.2011)

Current Rating

(30.09.2011)

Costa Rica

B1

B1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

IDENTIFICATION

 

CORRECT COMPANY NAME

MARPEL PHARMA S.A.

TAXPAYER REGISTRATION

CJ 3-101-388589

MAIN ADDRESS

Calle Mata Palo, Multibodegas No.7, frente al Colegio San José, Blue Valley, Guachipelín

CITY / PROVINCE

Escazú

DEPARTAMENT / STATE

San José

COUNTRY

COSTA RICA

TELEPHONE

(506) 22154215

FAX

(506) 22154214

E-MAIL

m.fillay@marpelpharma.com

WEB

www.marpelpharma.com

 

SUMMARY

 

Date of foundation

2004

Capital stock

US$50,000.= Dollars

Annual revenues

US$ 3,800,000.00 (30SEP2009)

permanent employees

50 (22 in Costa Rica, 28 in branches)

Chief Executive

UNGER SCHLAFRIG, PHILIP

Disposition

(They) refused to give information (only confirmed some data).

Payments policy

Usually to terms/good

 

CREDIT OPINION

 

Requested credit

MAXIMUM CREDIT

Suggested credit (*)

US$30,000.=

(*) After several opinions received and factors.

 

 

LEGAL BACKGROUNDS

 

LEGAL STATUS

Joint-Stock Company

DATE OF INCORPORATION

07/2004

PLACE OF REGISTRY

San Jose

DURATION

99 years

REGISTRATION

Volume 544, Entry 1840*

CURRENT PAID-IN CAPITAL

US$50,000.= Dollars

CLASS OF SHARES

Registered

LISTED AT STOCK EXCHANGE

No

CURRENT EXCHANGE RATE (US$)

C/.502.63 per US$1.= Dollar

COMMENTS

 
* Submission appointment.
It was not possible to find any information on who owns the 10% of remaining shares.

 

DIRECTORS - EXECUTIVES – SHAREHOLDERS

 

FULL NAMES / COMPANY NAME

TITLE

%PART.

SINCE

UNGER SCHLAFRIG, PHILIP

General Manager

90%

 

PALMA, RANDAL

Institutional Manager

 

 

FILLOY ZERR, MARIBEL

L.America RawMaterial Mgr

 

 

MOSES, GABRIELA

Administrative Manager

 

 

ABAUNZA ARGUELLO, CRISTINA

Director

 

 

JIMENEZ, KAREN

Biomedical Equipment Mgr

 

 

FELMAN, SALOMON

Central America Sales Mgr

 

 

MORALES, SANDRA

Reg.Affairs Mgr/Regulator

 

 

SOLIS, RONALD

Finance Manager

 

 

BONILLA, MARCO

General Accountant

 

 

 

 

WHO IS WHO?

 

UNGER SCHLAFRIG, PHILIP

NATIONALITY

Costa Rican

D.O.B.

01JUL1959

CIVIL STATUS

Married to Claire Vivian Senerman Cuchacovich

PROFESSION

Pharmacist

SEX

Male

 

ASSOCIATED AS PER OUR DATABASE TO

 

COMPANY

TITLE

TAX REG

COUNTRY

BIOPHAR DE PANAMA S.A.

Director

 

PANAMA

BIOPHAR CORPORATION

Director

 

PANAMA

 

BUSINESS HISTORY

 

 
As knowing the Latin American pharmaceutical market, a group of professionals, doctors, pharmacists, and specialists in marketing joined forces in July 2004 to establish Marpel Pharma.
Marpel Pharma S.A. is a distribution company in Costa Rica, with offices in other countries in Central America.
It offers generic products of the latest generation, manufactured under the highest standards and with the most modern technology at competitive prices.
Its market includes government entities, hospitals, clinics, and doctors.

 

 

 

 

 

 

RELATED COMPANIES TO SUBJECT COMPANY OR TO MAJORITY SHAREHOLDER

 

COMPANY NAME

COUNTRY

TAX REG.

RELATION %

GRUPO SALUD LATINA S.A.

COSTA RICA

3-101-273008

Related

 

 

BUSINESS

 

Main activity

 
Subject is engaged in import and trading of (finished) pharmaceutical products for human consumption, as well as inputs for manufacturing them.
It manufactures anti-anemia products, antibiotics, anti-inflammatory products, dermatologic products, ophthalmological products, etc. in different presentations.

Import

Yes

Country

(From Thailand, India, China, countries in Europe, and USA)

Export

Yes

COUNTRY

(To USA, El Salvador, Honduras, Nicaragua)

% CASH SALES / METHOD

50%

% Credit SALES / Terms

50% (Terms: 30, 60 days)

% Ventas exterior (Paises)

40%

% FOREIGN PURCHASES

100%

SELLING TerritorY

Domestic and international market

EMPLOYEES

50 (22 in Costa Rica, 28 in branches)

 

 

LOCATION

 

PREMISES

Own

AREA

500 m2

OTHER PREMISES

 
Subject's registered office and head offices are located on the above-mentioned address.
 
Subject has branches in Argentina, Guatemala, El Salvador, Mexico, India, and China. Those are rented premises.

Comments

 
Subject's customers are the social security and pharmaceutical companies.

 

 

FINANCIAL INFORMATION

 

Interviewee(s)

Mr. Marco Bonilla

Position(s)

General Accountant

Disposition

(They) refused to give information (only confirmed some data).

Information provided

 
Under confidentiality policies, he refused to provide any balance sheets.
 
We consulted third-party sources, official and archives, where it was found information included in this report.
 
Available information suggests that subject is a medium-sized, privately-held Costa Rican company that was incorporated in 2004. It makes use of commercial credits for moderate amounts that are paid without any problems. In consulted sources, it was not found any restrictions against subject.

 

 

FINANCIAL SITUATION

 
UNDETERMINED
This company's Financial Situation is deemed to be Undetermined because it was not found any financial information to assess its results.

 

 

 

 

 

INSURANCE

COMPANY

AGAINST

EXPIRATION

AMOUNT

INSTITUTO NACIONAL DE SEGUROS - INS

All risk

Annual

Not specified

 

PAYMENTS RECORD: TRADE REFERENCES

 

(Confidential Information)

Supplier: AGENCIA ADUANAL RCV ASESORIA INTERMODAL

Tel.: 22330003

Country: COSTA RICA

Goods/Services? : Customs services

 

 

Highest credit? : US$ 3,000-5,000.=

Outstanding debt? :

 

Client since? : 2008

Terms? : Invoice/30 days

Performance? : Prompt

Comments : AAA GOOD CUSTOMER

 

Note : Other suppliers did not provide information or could not be consulted

 

Supplier

Telephone

Country

Comment

ESKOY FINE CHEMICAL

91226 6222525

INDIA

 

SHANGHAI FARMACEUTICAL CO.

8621 65536699

CHINA

 

ALPA LABORATORIES LIMITED

91731 4294567

INDIA

 

 

 

BANKING INFORMATION

 

Bank

PROMERICA

LAFISE

 

Subject is a client of the above-mentioned banking entities, which did not provide any information on subject's banking movements under bank secrecy.

 

 

 

 

GENERAL INFORMATION

 

REPUTATION

 

NOTHING AGAINST COMPANY

 

 

 

 

CREDIT OPINION

 

Comnsulted Credit Amount :

MAXIMUM CREDIT

 

Suggested Credit :

US$30,000.=

 



NOTE : The opinion given is confidential, referential and with out liability.

 

 

 

FOREIGN EXCHANGE RATES

 

Currency
Unit

Indian Rupees

US Dollar

1

Rs.51.35

UK Pound

1

Rs.80.50

Euro

1

Rs.69.14

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

                                       New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.